 |
|
Vertebral Fracture Risk With Long-term Corticosteroid Therapy
Prevalence and Relation to Age, Bone Density, and Corticosteroid Use
Vasi Naganathan, FRACP;
Graeme Jones, FRACP, MD;
Peter Nash, FRACP;
Geoff Nicholson, FRACP;
John Eisman, FRACP, PhD;
Philip N. Sambrook, FRACP, MD
Arch Intern Med. 2000;160:2917-2922.
Background Few data are available regarding vertebral fracture risk in patients treated with oral corticosteroids. The aim of this study was to determine the prevalence and the role of risk factors such as age, bone mineral density (BMD), and corticosteroid use for vertebral deformity in patients receiving long-term corticosteroid therapy.
Methods Thoracolumbar x-ray films, BMD, and details on corticosteroid use were obtained on 229 consecutive patients treated with long-term corticosteroid regimens ( 6 months of prednisone, 5mg/d or equivalent) seen at 4 referral centers. Comparisons were made with a population control group of 286 male and female controls not taking corticosteroids (aged 60 years).
Results Sixty-five patients (28%) had at least 1 vertebral deformity and 25 (11%) had 2 or more vertebral deformities. Older age, independent of BMD, was a significant risk factor for deformity. Patients aged 70 to 79 years had a 5-fold increased risk of deformity compared with patients younger than 60 years (odds ratio, 5.13; 95% confidence interval, 2.03-13.0). Compared with the population controls, the prevalence of deformities increased to a greater extent with each decade of age in the corticosteroid group (P = .005). Mean lumbar spine and femoral neck BMD Z scores were lower in the steroid-treated patients with deformities compared with the nonsteroid control group with deformities. When the effects of age, sex, body mass index, and duration of corticosteroid use were adjusted for in logistic regression analysis, low BMD was a modest predictor of deformity (for a 1-SD decrease in lumbar spine BMD: odds ratio, 1.31; 95% confidence interval, 1.02-1.68) and for a 1-SD decrease in femoral neck BMD: odds ratio, 1.77; 95% confidence interval, 1.07-2.94).
Conclusions The combination of increasing age and corticosteroid use is associated with a marked increase in the risk of vertebral deformity. Elderly patients commencing long-term corticosteroid therapy should be considered for antiosteoporotic therapy independently of their BMD.
From the Department of Rheumatology, Institute of Bone and Joint Research, Royal North Shore Hospital, St Leonards, New South Wales (Dr Naganathan), Menzies Centre for Population Health Research, Hobart, Tasmania (Dr Jones), Sunshine Coast, Queensland (Dr Nash), Department of Medicine, Geelong Hospital, Geelong, Victoria (Dr Nicholson), Department of Medicine, Bone and Mineral Research Division, Garvan Institute of Medicine, St Vincent's Hospital, Sydney, New South Wales (Dr Eisman), and Department of Rheumatology, Institute of Bone and Joint Research, Royal North Shore Hospital, Sydney, New South Wales (Dr Sambrook), Australia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Osteoporosis and Fracture Risk Prevention in Long-term Glucocorticoid Therapy
Edin Karcic, Arsad A. Karcic, Vasi Naganathan, and Philip Sambrook
Arch Intern Med. 2001;161(14):1780-1781.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(19):3010-3011.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Age Dependence of Early Symptomatic Vertebral Fracture with High-Dose Glucocorticoid Treatment for Collagen Vascular Diseases
Tatsuno et al.
J. Clin. Endocrinol. Metab. 2009;94:1671-1677.
ABSTRACT
| FULL TEXT
Prevalence of Vertebral Fractures in Men with Acromegaly
Mazziotti et al.
J. Clin. Endocrinol. Metab. 2008;93:4649-4655.
ABSTRACT
| FULL TEXT
Relationship Between Pulmonary Emphysema and Osteoporosis Assessed by CT in Patients With COPD
Ohara et al.
Chest 2008;134:1244-1249.
ABSTRACT
| FULL TEXT
Anabolic Therapy in Glucocorticoid-Induced Osteoporosis
Sambrook
NEJM 2007;357:2084-2086.
FULL TEXT
Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids
van Staa et al.
Rheumatology (Oxford) 2007;46:460-466.
ABSTRACT
| FULL TEXT
Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis.
Syed et al.
Am. J. Neuroradiol. 2006;27:1938-1943.
ABSTRACT
| FULL TEXT
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
Da Silva et al.
Ann Rheum Dis 2006;65:285-293.
ABSTRACT
| FULL TEXT
A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids
van Staa et al.
QJM 2005;98:191-198.
ABSTRACT
| FULL TEXT
The Risk of Nonvertebral Fracture Related to Inhaled Corticosteroid Exposure Among Adults With Chronic Respiratory Disease
Johannes et al.
Chest 2005;127:89-97.
ABSTRACT
| FULL TEXT
Inhaled Corticosteroids and the Risk of Fractures in Children and Adolescents
Schlienger et al.
Pediatrics 2004;114:469-473.
ABSTRACT
| FULL TEXT
Vertebral Deformities in Rheumatoid Arthritis: A Comparison With Population-Based Controls
Orstavik et al.
Arch Intern Med 2004;164:420-425.
ABSTRACT
| FULL TEXT
Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables
Orstavik et al.
Ann Rheum Dis 2004;63:177-182.
ABSTRACT
| FULL TEXT
Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs
Adler and Hochberg
Arch Intern Med 2003;163:2619-2624.
ABSTRACT
| FULL TEXT
Preliminary clinical criteria had moderate sensitivity but low specificity for detecting osteoporosis in rheumatoid arthritis
Lane
Evid. Based Med. 2003;8:128-128.
FULL TEXT
Osteoporosis and Fracture Risk Prevention in Long-term Glucocorticoid Therapy
Karcic et al.
Arch Intern Med 2001;161:1780-1781.
FULL TEXT
|
